Abstract
Immune checkpoint inhibitors (ICIs) have improved clinical outcomes in triple-negative breast cancer (TNBC), but many patients (pts) do not respond to ICIs or will develop resistance. Combining VEGFR inhibition may potentiate ICI efficacy by normalizing vascular immune crosstalk and improving immune effector cell infiltration. Tislelizumab (T) is a humanized, IgG4-variant monoclonal antibody against PD-1. Fruquintinib (F) is a novel, highly selective, oral, tyrosine kinase inhibitor of VEGFR-1, 2, 3.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
